Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Inclusion Criteria:

- MSK patients diagnosed with breast cancer or have a mass suspicious of breast cancer
at the time of enrollment, as per clinician judgment or EMR;

- Self-reported current cigarette smoker (defined as daily smoking in the past seven
days)

- Advised to quit smoking by their MSK physician and willing to receive smoking
cessation counseling and treatment; as per self report

- Fluent in English

Exclusion Criteria:

- Patients less than 18 years of age because the safety and efficacy of varenicline
have not yet been tested in children;

- Evidence of any known or suspected medical contraindications for use of varenicline
(e.g., recent (within past two months) cardiovascular instability (including
myocardial infarction or unstable angina; uncontrolled hypertension, significant
neurological sequelae of cerebrovascular disease, or severe congestive heart failure
(New York Heart Association class III or IV), severe chronic obstructive pulmonary
disease; uncontrolled gastrointestinal, hepatic, or endocrine disease; or severe
renal impairment.

- Self-reported evidence of significant psychiatric history (e.g., schizophrenia,
unstable bipolar disorder, panic disorder, untreated major depression) sufficient, in
the investigators' judgment, to preclude participation in the clinical trial;

- Self-reported evidence of recent substance abuse or heavy alcohol use (> 14 drinks
weekly) in the last 6 months;

- Self-reported recent use (in the past 30 days) or planned use of nicotine replacement
therapy (NRT) or other FDA approved cessation pharmacotherapy (bupropion);

- Pre-menopausal women who are pregnant as per EMR

- Women who are breast-feeding as per self-report.